Determinination of the viral kinetics of human RSV M37 strain in newborn lambs for use in therapeutic testing and characterization of clinical signs and sickness behavior

Thumbnail Image
Date
2017-01-01
Authors
Larios, Alejandro
Major Professor
Advisor
Mark R. Ackermann
Michael J. Yaeger
Committee Member
Journal Title
Journal ISSN
Volume Title
Publisher
Altmetrics
Authors
Research Projects
Organizational Units
Organizational Unit
Veterinary Pathology
The Department of Veterinary Pathology Labs provides high quality diagnostic service to veterinarians in Iowa and throughout the Midwest. Packages may be delivered through the postage service or by dropping samples off at our lab in Iowa State University’s College of Veterinary Medicine campus.
Journal Issue
Is Version Of
Versions
Series
Abstract

Respiratory Syncytial Virus (RSV) is an enveloped single stranded RNA pneumovirus in the paramyxoviridae family that causes bronchiolitis and pneumonia in preterm and term newborns and elderly adults resulting in 75,000 to 125,000 hospitalizations of children below 1 year of age in the US each year.

Currently, there are no approved vaccines or effective therapeutic drugs for RSV infection, with treatment being solely limited to supportive care. One of the hurdles for developing vaccines or effective therapeutic drugs for RSV infection is a clinically relevant animal model. Animal models developed to study RSV infection include mice, cotton rats, ferrets, non-human primates, cattle, and lambs. Lambs have several biological features that closely mimic RSV infection in human infants such as: similarities to human infants in lung development, lung structure and airway branching, cellular composition and immune responses, and susceptibility to various strains of RSV including human strains (Long, A2, and Memphis Strain 37) for example.

To utilize the neonatal lamb model for therapeutic and vaccine studies, we characterized the viral kinetics of human M37 RSV strain to follow the progressive development of clinical signs, lung pathology and inflammatory/immune responses over time that closely resembled those of human infants. Once the viral kinetics of M37 were established, ALX-0171, a trivalent nanobody targeting the RSV F-protein was evaluated for its therapeutic potential, safety, and dose levels in newborn lambs infected with RSV M37. ALX-0171 was well-tolerated in RSV infected newborn lambs and exerted a positive effect on RSV-induced lung lesions while reduceing symptoms of illness.

To determine the clinical response(s) of the therapeutic drugs being tested, the use of video recording and surveillance was implemented to better define and correlate clinical signs and sickness behavior of RSV to severity of disease in the neonatal lamb model.

Comments
Description
Keywords
Citation
Source
Subject Categories
Copyright
Sun Jan 01 00:00:00 UTC 2017